TESAMORELIN 10 MG / IPAMORELIN 3 MG — 13 MG

Description

DESCRIPTION

Tesamorelin + Ipamorelin is a research blend combining a synthetic growth hormone-releasing hormone (GHRH) analog (Tesamorelin) with a selective ghrelin receptor agonist (Ipamorelin). It is studied in research models for combined GHRH and ghrelin receptor pathway activity and downstream growth hormone axis signaling.

RESEARCH AREAS

• Dual-pathway GH axis activity — studied for simultaneous GHRH receptor and ghrelin receptor engagement in cell-based assays.
• Pituitary signaling research — investigated in preclinical models for combined pathway activation.
• Comparative secretagogue research — characterized alongside single-compound GHRH and ghrelin receptor research peptides.
• Receptor selectivity profile — studied in published literature for combined receptor binding characteristics.

WHAT RESEARCHERS LOOK AT

• Mechanism: combined GHRH receptor and ghrelin receptor (GHS-R1a) agonism.
• Comparative pathway activation versus single-compound research peptides.
• Receptor selectivity profiles in vitro.
• Applications in GH axis and pituitary research models.

QUICK SPECS

• • Form: Lyophilized peptide blend
  • Net per vial: 13 mg
  • Purity: ≥99% (HPLC)

• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light

IDENTITY BASICS

• Type: GHRH analog + selective ghrelin receptor agonist blend
• Components: Tesamorelin (44-aa GHRH analog) + Ipamorelin (pentapeptide)

SELECTED RESEARCH

• Tesamorelin — PubChem entry:
  https://pubchem.ncbi.nlm.nih.gov/compound/16139605
• Ipamorelin — PubChem entry:
  https://pubchem.ncbi.nlm.nih.gov/compound/16132392
• GHRH and ghrelin receptor pathway research:
  https://pubmed.ncbi.nlm.nih.gov/15240392/

⚠️ DISCLAIMER

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.